

1 8/25/2021 6:52 PM

2  
3  
4 **Oxo-M and 4-PPBP Delivery via Multi-Domain Peptide Hydrogel Toward Tendon**  
5 **Regeneration**

6  
7 <sup>1</sup>Ga Young Park, PhD

8 <sup>1</sup>Solaiman Tarafder, PhD

9 <sup>1</sup>Samantha Lewis, BS

10 <sup>1</sup>Soomin Park, BS

11 <sup>1</sup>Ryunhyung Park, BS

12 <sup>2</sup>Zain Siddiqui, MS

13 <sup>2</sup>Vivek Kumar, PhD

14 <sup>1</sup>Chang H. Lee, PhD\*

15  
16  
17 <sup>1</sup>Regenerative Engineering Laboratory  
18 Center for Dental and Craniofacial Research  
19 Columbia University Irving Medical Center  
20 630 West 168<sup>th</sup> Street, VC12-211  
21 New York, NY 10032

22  
23 <sup>2</sup>New Jersey Institute of Technology  
24 Department of Bio-Medical Engineering  
25 138 Warren St., Room 316, Newark, NJ, 07102

26  
27  
28 **Short title: Multi-Domain Peptides tune small molecule release driving Tendon**  
29 **Regeneration**

30  
31  
32  
33 **\*Corresponding author**

34 Chang H. Lee, PhD

35 Associate Professor, Regenerative Engineering Laboratory

36 Associate Director, Center for Dental and Craniofacial Research

37 Columbia University Irving Medical Center

38 630 West 168<sup>th</sup> street, VC12-211B

39 New York, NY 10032

40 Phone: 212-305-1920

41  
42 Email: [chl2109@cumc.columbia.edu](mailto:chl2109@cumc.columbia.edu)

43  
44  
45  
46

47 **Abstract**

48 We have recently identified novel small molecules, Oxo-M and 4-PPBP, which specifically  
49 stimulates endogenous tendon stem/progenitor cells (TSCs) leading to potential regenerative  
50 healing of fully-transected tendons. Here we investigated an injectable, multi-domain peptide  
51 (MDP) hydrogel providing a controlled delivery of the small molecules for regenerative tendon  
52 healing. We investigated the release kinetics of Oxo-M and 4-PPBP from MDP hydrogels and  
53 the effect of MDP-released small molecules on tenogenic differentiation of TSCs and *in vivo*  
54 tendon healing. *In vitro*, MDP showed a sustained release of Oxo-M and 4-PPBP and a slower  
55 degradation compared to fibrin. In addition, tenogenic gene expression was significantly  
56 increased in TSC with MDP-released Oxo-M and 4-PPBP as compared to the fibrin-released. *In*  
57 *vivo*, MDP releasing Oxo-M and 4-PPBP significantly improved tendon healing, likely associated  
58 with prolonged effects of Oxo-M and 4-PPBP on suppression of M1 macrophages and  
59 promotion of M2 macrophages. Comprehensive analyses including histomorphology, digital  
60 image processing, and modulus mapping with nanoindentation consistently suggested that Oxo-  
61 M and 4-PPBP delivered via MDP further improved tendon healing as compared to fibrin-based  
62 delivery. In conclusion, MDP delivered with Oxo-M and 4-PPBP may serve as an efficient  
63 regenerative therapeutic for in situ tendon regeneration and healing.

64

65 **Key Terms:** Tendon regeneration, small molecules, tendon stem/progenitor cells, multi-domain  
66 peptide, controlled delivery.

67

68

## 69 Introduction

70

71 Tendons are dense fibrous tissues with the primary function of transferring mechanical forces  
72 from muscle to bone. Injuries to tendons can be caused by laceration, contusion or tensile  
73 overload, which account for 50% of all musculoskeletal injuries in the U.S (1-5). For example,  
74 rotator cuff injuries affect over 30% of Americans over 60 years of age, leading to over 50,000  
75 surgical repairs annually (6-8). Approximately 11% runners in the U.S. suffer from Achilles  
76 tendinopathy (6), and there are 5 million new cases of tennis elbow (lateral epicondylitis) each  
77 year (6). This results in a large healthcare burden with treatment for treating tendon injuries  
78 exceeding \$30 billion per year in the U.S alone (6, 9). Injuries to adult tendons do not  
79 spontaneously heal and frequently end up with scar-like tissue - exhibiting high cellularity,  
80 disarrayed collagen fibers, and poor mechanical properties (5, 10).

81

82 To improve tendon healing, various cell types including tenocytes, dermal fibroblasts and  
83 stem/progenitor cells have been applied in tendon tissue engineering *in vitro* or in animal  
84 models (9, 11-23). Promising progress has been made in stem cell-based tendon regeneration  
85 *in vitro* and in animal models, despite the lack of clinical availability (18, 19, 24). Recently, we  
86 devised a novel *in situ* tissue engineering approach for tendon regeneration by activating  
87 endogenous stem/progenitor cells (25). We have identified perivascular-originating TSCs that  
88 are capable of guiding regenerative healing of tendons when stimulated by connective tissue  
89 growth factor (CTGF) (25). Further investigation into molecular mechanisms of action led us to  
90 the discovery of a combination of small molecules, Oxo-M and 4-PPBP sharing intracellular  
91 signaling with CTGF, which promotes tendon healing by harnessing endogenous TSCs (26). In  
92 addition, our data suggested that Oxo-M and 4-PPBP specifically target CD146<sup>+</sup> TSCs via  
93 muscarinic acetylcholine receptors (AChRs) and sigma 1 receptor ( $\sigma$ 1R) pathways (26). Given no  
94 need for cell isolation, culture-expansion and transplantation, *in situ* tendon regeneration by  
95 delivery of Oxo-M and 4-PPBP has significant translational potential (27).

96

97 Despite a number of advantages (27), small molecule-based regenerative therapies have  
98 several limitations. A major outstanding challenge is the fast release of small molecules, likely  
99 linked with reduced bioactivity *in vivo* (26). This may serve as a major roadblock in the  
100 development of Oxo-M and 4-PPBP as a regenerative therapeutics applicable in large, pre-  
101 clinical animal models and humans for which tendon healing likely take a longer than in small  
102 animal models (28). Previously, we have investigated efficacy of a controlled delivery of Oxo-M  
103 and 4-PPBP via poly(lactic-co-glycolic acids) (PLGA) microspheres ( $\mu$ S) (26). Sustained release  
104 of Oxo-M and 4-PPBP from PLGA  $\mu$ S resulted in a significant enhancement in tendon healing  
105 (26). However, degradation byproducts of PLGA potentially lower local pH, possibly leading to  
106 inflammation and disrupted tissue healing (29, 30). Accordingly, a biocompatible, reliable,  
107 injectable and safe vehicle for controlled release of Oxo-M and 4-PPBP is required for facile  
108 translation.

109

110 In this study, we applied an injectable and self-assembling multi-domain peptide (MDP)  
111 hydrogel (31, 32) for controlled delivery of Oxo-M and 4-PPBP. MDP hydrogel is composed of  
112 the sequence KKSLSLRGSLSLKK (termed K2). MDP self-assembles into  $\beta$ -sheets that  
113 further form entangled fibrous meshes (31, 32). These highly hydrated meshes generate  
114 nanofibrous hydrogels that can be tuned to promote controlled delivery of various bioactive cues

115 (31, 32). Our previous studies confirmed biocompatibility and non-acidic degradation products of  
116 MDP (31, 32). Here, we investigated the efficacy of MDP hydrogel with sustained release of  
117 Oxo-M and 4-PPBP both *in vitro* and *in vivo* in regard to tenogenic differentiation of TSCs,  
118 macrophage polarization and tendon healing.

119

## 120 **Materials and Methods**

121

### 122 ***Isolation and sorting of CD146<sup>+</sup> TSC***

123 CD146<sup>+</sup> TSCs were isolated from patella tendons (PT) of 12 wks old Sprague-Dawley (SD) rats,  
124 as per our prior methods (25). Briefly, the harvested PT was cleaned, minced and then digested  
125 in 2 mg/ml collagenase at 37°C for 4 hours. After centrifugation of the digest, the pellet was re-  
126 suspended in Dulbecco's Modified Eagle Medium-Low Glucose (DMEM-LG; Sigma, St. Louis,  
127 MO) containing 10% fetal bovine serum (FBS; Gibco, Invitrogen, Carlsbad, CA) and 1%  
128 penicillin-streptomycin antibiotic (Gibco, Invitrogen, Carlsbad, CA). Then CD146<sup>+</sup> cells were  
129 sorted using a magnetic cell separation kit (EasySep™, StemCells™ Technologies, Cambridge,  
130 MA).

131

### 132 ***MDP hydrogel for controlled delivery of Oxo-M and 4-PPBP***

133 Multi-domain peptides (MDP) were designed based on previously published sequences: SL:  
134 K<sub>2</sub>(SL)<sub>6</sub>K<sub>2</sub> (32). All peptides, resin and coupling reagents were purchased from CEM (Charlotte,  
135 NC). Standard solid phase peptide synthesis was performed on a CEM Microwave peptide  
136 synthesizer using Rinkamide resin with 0.37 mM loading, with C-terminal amidation and N-  
137 terminal acetylation. Post cleavage from resin, peptides were dialyzed with 500 - 1200 MWCO  
138 dialysis tubing (Sigma-Aldrich, St. Louis, MO) against DI water. Peptides were subsequently  
139 lyophilized, confirmed for purity using electron-spray ionization mass spectrometry, MicroTOF  
140 ESI (Bruker Instruments, Billerica, MA), and reconstituted at 20 mg/ml (20 wt%) in sterile 298  
141 mM sucrose. Gelation of peptide was achieved by addition of volume equivalents of pH 7.4  
142 buffer with 1" PBS or HBSS. Then Oxo-M (10 mM) and 4-PPBP (100 μM) were loaded at 10 –  
143 50 μl in 1 ml of MDP. *In vitro* release profiles were measured by incubating 1 ml of MDP  
144 hydrogel encapsulated with Oxo-M or 4-PPBP in PBS or 0.1% BSA at 37 °C with a gentle  
145 agitation. The samples were centrifuged at the selected time points, followed by measuring  
146 concentrations in the supernatants with a UV-Vis spectroscope (Nanodrop™ 2000,  
147 ThermoFisher Scientific, Waltham, MA) at 230 nm and 207 nm wavelengths for Oxo-M and 4-  
148 PPBP, respectively.

149

### 150 **MDP degradation**

151 For *in vitro* degradation test, MDP hydrogel was prepared with and without Oxo-M and 4-PPBP,  
152 as labeled with Alexa Fluor® 488 dye. Fibrin gel (50 mg/ml fibrinogen and 50 U/ml thrombin) with  
153 and without Oxo-M and 4-PPBP was prepared as a comparison group. The final concentrations  
154 of Oxo-M and PPBP in Fibrin gel and MDP were 1 mM and 10 μM, respectively. Then an equal  
155 volume (80 μL) of each gel (N = 3) was placed into wells of 24-well plate and kept into PBS for  
156 the duration of the study. At pre-determined time points, fluorescent images of the samples  
157 were taken using Maestro™ *in vivo* fluorescence imaging system (Cambridge Research &  
158 Instrumentation, Inc., Woburn, MA, USA). The images were processed by Image J to calculate  
159 percent degradation from the area of the remaining gels.

160

161 ***In vitro assessment for efficacy of sustain-released Oxo-M and 4-PPBP***

162 Efficacy of sustained release of Oxo-M and 4-PPBP from MDP hydrogel were tested for TSCs  
163 differentiation with transwell co-culture. Briefly, MDP encapsulated with Oxo-M and 4-PPBP  
164 were applied to Transwell® inserts with 0.4 µm pore membrane, where TSCs (80 – 90%  
165 confluence) cultured on the bottom wells. This co-culture model allows transportation of the  
166 released small molecules while preventing a direct contact between cells and MDP. At 1 wk  
167 culture with tenogenic induction supplements (25), total RNA were harvested and mRNA  
168 expressions of tendon related genes including collagen type I and III (COL-I & III), tenascin-C  
169 (Tn-C), vimentin (VIM), tenomodulin (TnmD), fibronectin (Fn) and scleraxis (Scx) were  
170 measured by quantitative RT-PCR using Taqman™ gene expression assay (Life Technologies;  
171 Grand Island, NY) as per our established protocols (25). The quantitative measures for  
172 tenogenic differentiation of TSCs by control-delivered Oxo-M and 4-PPBP were compared with  
173 release from fibrin gel (50 mg/ml fibrinogen + 50 U/ml thrombin).

174

175 ***In vivo tendon healing by a controlled delivery of Oxo-M and 4-PPBP***

176 MDP-encapsulated with Oxo-M and 4-PPBP were delivered into fully transected rat patellar  
177 tendon (PT) as per prior works (25). Briefly, all animal procedures followed an IACUC approved  
178 protocol and 12 wks old Sprague-Dawley (SD) rats (n = 4 per group and time point) were used.  
179 Upon anesthesia, a 10-mm longitudinal incision were made just medial to the knee. After  
180 exposing PT, a full-thickness transverse incision was made using a no. 11 blade scalpel. MDP  
181 hydrogel with or without Oxo-M & 4-PPBP was applied on the transection site. After creating a  
182 bone tunnel at the proximal tibia using a 0.5 mm drill, a 2-0 Ethibond suture (Ethicon Inc,  
183 Somerville, NJ, USA) was passed through the tibial tunnel and quadriceps in a cerclage  
184 technique. The surgical site was then closed using 4.0 absorbable (continuous stitch) for the  
185 subcutaneous layer and 4.0 PDS and monocryl (interrupted stitches) for the skin closure. At 2  
186 wks post-op, animals were euthanized and the quality of tendon healing in association with  
187 endogenous TSCs were analyzed using H&E, Picrosirius-red (PR) polarized imaging,  
188 automated quantitative imaging analysis for collagen fiber orientation. To image whole tissue  
189 sections containing any spatial features, slide scanning was performed using Aperio AT2  
190 scanner (Leica Biosystems Inc., Buffalo Grove, IL). From H&E stained tissue sections (n = 10  
191 per group), the quality of tendon healing was quantitatively evaluated using a modified Watkins  
192 scoring system (33), covering cellularity, vascularity, cell alignment, amount and size of collagen  
193 fibers and wave formation. In addition, immunofluorescence (IF) was performed for macrophage  
194 polarization markers, including inducible nitric oxide synthase (iNOS) (PA1-036, Thermo  
195 Fisher), and CD163 (NMP2-39099, Novus Biologicals), as co-labeled with DAPI. Anti-  
196 inflammatory cytokine IL-10 (AF519-SP, Novus Biologicals) and tissue inhibitor of  
197 metalloproteinases-3 (TIMP-3) (ab39184, Abcam) were also evaluated using IF. The labeled  
198 tissue sections were imaged using Aperio AT2 scanner with fluorescence.

199

200 ***Automated image analysis for collagen alignment***

201 As per our well-established methods (25, 26, 34), we analyzed the collagen fiber orientation in  
202 PR stained tissue sections using a digital image processing technique. Briefly, the local  
203 directionality and angular deviation (AD) in circularly polarized PR-stained images were  
204 calculated by the automated image-processing method. The analysis of each image yielded a  
205 distribution of fiber orientations, ranging from -90° to 90°, where 0° was defined as the vertical  
206 direction. The degree of collagen fiber alignment was quantified using the AD. The value of the

207 AD was calculated using circular statistics (25, 34) implemented with MATLAB (Mathworks Inc.,  
208 Natick, MA, USA). For the digital imaging processing, total 15 different image samples were  
209 used per group.

210

### 211 **Modulus mapping with nanoindentation**

212 To assess the maturation and homogeneity of extracellular matrix (ECM) in the healing zone,  
213 we performed modulus mapping with nanoindentation on tendon section as per well-established  
214 methods (35). Briefly, the nanoindentation was conducted using a PIUMA™ nano-indenter  
215 (Optics11, Amsterdam, The Netherlands) with a 1- $\mu$ m probe. The unfixed and unstained tissue  
216 sections were mounted on the embedded high-precision mobile X-Y stage and a maximum  
217 force of 10 mN was applied at every 20  $\mu$ m distance from the original defect site to determine  
218 the effective indentation modulus ( $E_{\text{Eff}}$ ) across a healed region over selected 400  $\mu$ m x 400  $\mu$ m  
219 area. The measured  $E_{\text{Eff}}$  values were displayed in XYZ plane to visualize their homogeneity over  
220 unit area. Then the  $E_{\text{Eff}}$  values from control, fibrin with Oxo-M and 4-PPBP (Fib + OP), and MDP  
221 + OP groups were normalized to those of intact region in the corresponding tendon samples.

222

### 223 **Effect of Oxo-M and 4-PPBP on macrophage polarization**

224 Given the essential roles of macrophages during tendon healing (36), we evaluated effect of  
225 Oxo-M and 4-PPBP on macrophage polarization *in vitro*. Briefly, THP-1 human monocytes  
226 (ATCC®, Manassas, VA) were cultured in complete RPMI media (ThermoFisher Scientific,  
227 Waltham, MA), supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin  
228 (37). For differentiation of THP-1 monocytes into un-activated (M0) macrophages, phorbol 12-  
229 myristate 13-acetate (PMA) was applied at 320 nM for 16 hours. For M1 polarization, 100 ng/mL  
230 of lipopolysaccharide (LPS) and 100 ng/mL of recombinant human interferon- $\gamma$  (IFN- $\gamma$ ) were  
231 applied for 48 hours. For M2 polarization, 40 ng/mL of recombinant human interleukin-4 (IL-4)  
232 and 20 ng/mL of recombinant human IL-13 were applied as per well-established protocols (37).  
233 Oxo-M (1 mM) and 4-PPBP (10  $\mu$ M) were applied along with the M1 and M2 polarization stimuli.  
234 After 48 hours, all cells were detached by gentle scraping, followed by RNA isolation for qRT-  
235 PCR analysis for M1 and M2 polarization mRNA markers, including tumor necrosis factor alpha  
236 (TNF- $\alpha$ ), IL-1 $\beta$ , Mannose receptor C-type 1 (MRC1), platelet derived growth factor b (PDGFb).

237

### 238 **Statistical analysis**

239 For all the quantitative data, following confirmation of normal data distribution, one-way analysis  
240 of variance (ANOVA) with post-hoc Tukey HSD tests were used with p value of 0.05. Sample  
241 sizes for all quantitative data were determined by power analysis with one-way ANOVA using a  
242 level of 0.05, power of 0.8, and effect size of 1.50 chosen to assess matrix synthesis, gene  
243 expressions, and structural properties in the regenerated tendon tissues and controls.

244

## 245 **Results**

246

### 247 ***Sustained release of Oxo-M and 4-PPBP from MDP hydrogel promotes tenogenic*** 248 ***differentiation***

249 *In vitro* release kinetics showed that Oxo-M and 4-PPBP are fully released from fibrin within 3 –  
250 4 days (**Fig. 1B**). However, Oxo-M and 4-PPBP showed sustained release from MDP up to 14 –  
251 25 days (**Fig. 1C**). Expressions of tendon-related genes, including COL-I & III, Tn-C, TnmD, Fn  
252 and Scx, were significantly increased in TSCs cultured under Trans-well insert loaded with Oxo-


253 M and 4-PPBP in fibrin or MDP hydrogel, in comparison with control with no treatment by 1 wk  
254 (**Fig. 1D**) (n = 5 per group; p<0.001). In addition, all the tested tenogenic gene expressions were  
255 significantly higher in MDP + OP than Fib + OP (**Fig. 1D**) (n = 5 per group; p<0.001), suggesting  
256 positive effect of a prolonged release from MDP hydrogel.

257

### 258 **In vitro degradation**

259 Images of fluorescence-labeled hydrogels showed the remaining amount of fibrin and MDP  
260 hydrogels over the course of *in vitro* degradation (**Fig. 2A**). Fibrin appeared to fully degrade by 4  
261 days *in vitro* with and without Oxo-M and 4-PPBP. In contrast, MDP hydrogel showed muted  
262 degradation by 11 days *in vitro* (**Fig. 2A**). Quantitative fluorescence signal strength measured  
263 by Maestro™ imaging system consistently showed that MDP showed ~48% volumetric  
264 reduction by 11 days, which is significantly slower than fibrin gel showing a 100% degradation  
265 by 4 days (**Fig. 2B**). In addition, delivering Oxo-M and 4-PPBP in the MDP hydrogel significantly  
266 accelerated the *in vitro* degradation (**Fig. 2B**).

267



268

269 **Figure 1.** Multi-domain peptide (MDP) hydrogel as controlled delivery vehicle for Oxo-M and 4-

270 PPBP. MDP self-assembles supra-molecularly into nanofibers that encapsulate drugs, while

271 maintaining shear thinning and shear recovery properties (**A**). This allows for facile aspiration

272 and delivery as depots into tissue sites for localized release of small molecule drugs from

273 biodegradable peptide scaffolds. Oxo-M and 4-PPBP loaded in fibrin gel were fully released by

274 3 – 4 days (**B**), whereas they showed sustained release from MDP hydrogel up to 25 days (**C**).

275 Tenogenic gene expressions were significantly higher in TSCs cultured under Transwell® inserts


276 with fibrin and MDP hydrogel releasing Oxo-M and 4-PPBP (**C**). Oxo-M and 4-PPBP release

277 from MDP hydrogel resulted in significantly higher gene expressions as compared to what

278 released from fibrin (**D**) (n = 5 per group; \*: p<0.001 compared to fibrin group; #:p<0.001

279 compared to control).

280




281  
282 **Figure 2.** *In vitro* degradation of MDP and fibrin gel with and without Oxo-M and 4-PPBP.  
283 Fluorescence-labeled fibrin and MDP with or without Oxo-M and 4-PPBP (OP) were imaged (**A**)  
284 and the integral of signal intensities were quantified (**B**) (n = 3 per group).  
285

### 286 **MDP delivered with Oxo-M and 4-PPBP enhanced tendon healing in vivo**

287 Fully transected rat PT without treatment ended up with scar-like healing with high cellularity,  
288 lacked collagen matrix and disrupted collagen orientation by 2 wks post-op (**Fig. 3A, D, G & J**).  
289 In contrast, Oxo-M and 4-PPBP delivery via fibrin and MDP hydrogel significantly enhanced  
290 tendon healing with significantly improved structure (**Fig. 3B & E**), dense collagen deposition  
291 (**Fig. 3H**), and re-orientation of collagen fibers (**Fig. 3K**) in comparison with control. Few tissue  
292 samples in fibrin/Oxo-M and 4-PPBP (Fib + OP) group showed somewhat suboptimal healing  
293 (**Fig. 3B**), whereas MDP/Oxo-M and 4-PPBP (MDP + OP) resulted in more consistent healing  
294 outcome (**Fig. 3C**). Similarly, the collagen fibers appeared to be denser and better aligned in  
295 MDP + OP group as compared to Fib + OP group (**Fig. 3I & L**). In addition, MDP + OP resulted  
296 in a significantly higher histological score with smaller variance as compared to Fib + OP with a  
297 larger variance (**Fig. 3M**). Consistently, quantitative imaging processing showed that the degree  
298 of collagen alignment quantified as AD value was superior with MDP + OP to Fib + OP (**Fig. 3N**)  
299 (n = 15 per group; p<0.001).






300  
 301 **Figure 3.** *In vivo* tendon healing by 2 wks. The control ended up with scar-like healing with  
 302 disrupt matrix and high cellularity (A, D), whereas fibrin and MDP delivered with Oxo-M and 4-  
 303 PPBP showed notable improvement in tendon healing (B, C, E, F). Masson's trichrome showed  
 304 higher collagen deposition in the healing zone with Oxo-M and 4-PPBP delivery via fibrin and  
 305 MDP (G-I). Polarized PR images showed higher collagen orientation with MDP + OP as  
 306 compared to fibrin + OP (J-K). There were some variances in the healing outcome with fibrin +  
 307 OP (B, E, H, K) in comparison with more consistent outcome with MDP + OP (C, F, I, L).  
 308 Quantitatively, MDP + OP resulted in significantly higher histological scores with a relatively  
 309 small variance as compared to Fib + OP (M) (n = 10 – 25 per sample; \*:p<0.001 compared to  
 310 control; #: p<0.001 compared to Fib + OP). Quantitative angular deviation (AD) value was  
 311 significantly lower with MDP + OP as compared to fibrin + OP and control (N) (p<0.0001; n = 10  
 312 – 15 per group). All images are representative best outcome for each group.

313  
 314 ***MDP + OP improved magnitude and distribution of indentation moduli***

315 Modulus mapping with nanoindentation displayed the distributions of effective indentation  
 316 modulus ( $E_{\text{Eff}}$ ) over 400  $\mu\text{m}$  x 400  $\mu\text{m}$  areas in the healing regions (Fig. 4A-C). Control group  
 317 showed lower  $E_{\text{Eff}}$  values with somewhat homogeneous distribution (Fig. 4A). Fib + OP showed  
 318 higher  $E_{\text{Eff}}$  values with a less homogenous distribution (Fig. 4B), and MDP + OP showed a  
 319 highly homogenous distribution (Fig. 4C). Quantitatively, control group showed a lower average  
 320  $E_{\text{Eff}}$  at healing zone than intact tendon, whereas Fib + OP showed average  $E_{\text{Eff}}$  significantly  
 321 higher than control (Fig. 4D) (n = 100 – 150 per group; p<0.0001). MDP + OP showed  $E_{\text{Eff}}$  at  
 322 the similar level with intact tendons (Fig. 4D) (n = 100 – 150 per group; p<0.0001). Consistently  
 323 with  $E_{\text{Eff}}$  distribution (Fig. 4A-C), MDP + OP showed smaller variance in  $E_{\text{Eff}}$  than Fib + OP (Fig.  
 324 4D).

325




326  
 327 **Figure 4.** Modulus mapping by nanoindentation of tendon sections (**A-C**), showing more  
 328 homogenous distribution of indentation moduli with MDP + OP as compared to Fib + OP.  
 329 Relative effective modulus ( $E_{\text{Eff. Rel}}$ ) at healing zone in respect to corresponding intact area (**D**)  
 330 were significantly higher in Fib + OP and MDP + OP than control.  $E_{\text{Eff. Rel}}$  showed larger  
 331 variance in Fib + OP than MDP + OP ( $n = 100 - 150$  per group;  $*:p<0.0001$  compared to control;  
 332  $\#:p<0.0001$  compared to Fib + OP).

333

### 334 Effect of Oxo-M and 4-PPBP on macrophage polarization

335 By 48 hours of M1 polarization of THP-1 derived macrophages induced by LPS and IFN- $\gamma$ , the  
 336 treatment with OP significantly reduced mRNA expressions of TNF- $\alpha$  and IL-1 $\beta$  (**Fig. 5A**). In  
 337 contract, Oxo-M and 4-PPBP significant promoted M2 polarization induced by IL-4 and IL-10,  
 338 with elevated levels of MRC1 and PDGFb (**Fig. 5A**) ( $n = 6$  per group;  $*:p<0.001$ ). *In vivo*, OP  
 339 delivery via fibrin and MDP resulted in a significantly lower number of iNOS $^+$  M1-like cells by 2  
 340 wks post-op (**Fig. 5B**). The number of CD163 $^+$  M2-like macrophages was significantly increased  
 341 with OP delivery (**Fig. 5B**). In addition, MDP + OP showed more M2-like CD163 $^+$  cells as  
 342 compared to Fib + OP (**Fig. 5B**).

343



344  
 345 **Figure 5.** Effect of Oxo-M and 4-PPBP on macrophage polarization (**A**) ( $*:p<0.001$  compared  
 346 control). Immunofluorescence of macrophage and anti-inflammatory markers (**B**). The number  
 347 of iNOS $^+$  M1-like macrophages were lower with OP delivery (**B**). MDP + OP showed an

348 increased number of CD163+ M2-like cells as compared to fibrin + OP (**B**). TIMP-3 and IL-10  
349 showed robust expression in MDP + OP group in comparison with Fib + OP (**B**).

350

## 351 **Discussion**

352

353 Our findings suggest an effective and reliable approach to enable a controlled delivery of small  
354 molecules that improve regenerative tendon healing by harnessing endogenous stem/progenitor  
355 cells. The unique chemical characteristics of MDP hydrogels, self-assembling into  $\beta$ -sheets,  
356 enable entrapment of small molecular weight drugs such as Oxo-M and 4-PPBP, consequently  
357 providing sustained release over time. Given that MDP self-assembles through noncovalent  
358 interactions of alternating hydrophobic leucine residues and hydrogen bonding of hydrophilic  
359 serines (32), both hydrophilic Oxo-M and hydrophobic 4-PPBP were able to be loaded into MDP  
360  $\beta$ -sheet and then showing sustained release without notable difference in the release kinetics  
361 between Oxo-M and 4-PPBP (**Fig. 1B & C**). In contrast to the previously used PLGA  $\mu$ S, MDP's  
362 degradation byproducts do not change local pH with a good biocompatibility established in a  
363 number of prior studies (32). In addition, its unique near instantaneous self-assembly in  
364 aqueous solution allows drug solubilization and facile injection of MDP hydrogels in desired sites  
365 via a syringe needle, followed by near-instant *in situ* gelation (32). These characteristics further  
366 advocate the potential of MDP hydrogels as an efficient controlled delivery vehicle.

367

368 A prolonged release of Oxo-M and 4-PPBP from MDP appeared not only to enhance tenogenic  
369 differentiation of TSCs but also to modulate polarization of macrophages. Our *in vitro* data  
370 suggest that Oxo-M and 4-PPBP may interfere with M1 polarization while promoting M2  
371 polarization. Collective experimental evidences in several previous studies support the temporal  
372 roles of inflammatory of M1 macrophages and anti-inflammatory M2 macrophages in the early  
373 and late phases of tendon healing, respectively (35, 38-40). Excessive or prolonged M1  
374 macrophages are closely involved with inflammation and scarring, whereas M2 macrophages  
375 play essential roles in matrix synthesis and remodeling (35, 38-40). Thus, prolonged activities of  
376 Oxo-M and 4-PPBP via controlled delivery with MDP may have promoted tendon healing by  
377 attenuating M1-mediated inflammation and M2-mediated anti-inflammatory cytokines and matrix  
378 remodeling. Consistently, we have observed the elevated levels of TIMP-3 and IL-10 with MDP  
379 + OP as compared to Fib + OP by 2 wks post-op.

380

381 The modulus mapping on sectioned tendon tissues by nanoindentation revealed interesting  
382 features on healed ECM (**Fig. 4**). Scar-like matrix formed in control group showed a relatively  
383 homogenous distribution of indentation modulus with high moduli at isolated area (**Fig. 4A**).  
384 Tendon tissue healed with OP delivered via fibrin gel increased the average indentation  
385 modulus but showed substantial inhomogeneity over the testing area (**Fig. 4B**). Notably, tendon  
386 delivered with MDP + OP resulted in increased indentation moduli with highly homogenous  
387 distribution (**Fig. 4C**). These observations may suggest that relatively inhomogeneous matrix in  
388 Fib + OP is likely due to immaturity of healed tendon matrix, and more mature tissue matrix in  
389 MDP + OP group was formed by a prolonged release of OP leading to sustained activation of  
390 M2 macrophages modulating inflammation and matrix remodeling.

391

392 Despite the promising outcomes, our study has several limitations that includes the unknown *in*  
393 *vivo* degradation rate. Most biodegradable materials exhibit *in vivo* degradation rates markedly

394 variant from well-controlled *in vitro* studies (41, 42), likely associated with dynamic changes in  
395 the biochemical environment *in vivo* affected by inflammation, cell metabolism, and co-  
396 morbidities (41, 42). Thus, the actual degradation of MDP hydrogel and consequent release of  
397 Oxo-M and 4-PPBP may differ from the *in vitro* data. Nonetheless, such *in vivo* factors are  
398 speculated to affect degradation of both fibrin and MDP, consequently validating our  
399 comparative *in vivo* study between the two different delivery vehicles. Various state-of-art  
400 imaging modalities are being developed to track *in vivo* degradation and release via non-  
401 invasive measurements (43-45), which will likely serve as an efficient tool to further optimize  
402 delivery vehicles in follow-up studies.

403

404 In conclusion, MDP may represent a highly efficient, injectable hydrogel system allowing  
405 controlled delivery of Oxo-M and 4-PPBP with specific function to stimulate endogenous  
406 stem/progenitor cells and modulate macrophages toward tendon regeneration. Given no need  
407 for cell translation, our approach with MDP releasing Oxo-M and 4-PPBP has significant clinical  
408 impact as a highly translational approach to induce regenerative healing of tendons.

409

#### 410 **Acknowledgements**

411 We thank Aryan Mahajan for creation of the schematics in Figure 1A. **Funding:** This study is  
412 supported by NIH Grants 5R01AR071316-04 and 1R01DE029321-01A1 to C.H.L and NIH NEI  
413 R15EY029504 for V.A.K. **Author contributions:** G.P. was responsible for the primary technical  
414 undertaking and conducted the experiments. S.L. assisted nanoindentation modulus mapping.  
415 S.P. and R.P. assisted histomorphological analysis. S.T. performed *in vivo* animal surgeries,  
416 digital imaging processing and nanoindentation experiment. Z.S and V.K. are responsible for  
417 synthesis and purification of peptide hydrogel. C.H.L. is responsible for the study design, data  
418 analysis and interpretation, and manuscript preparation. All the authors edited the manuscript.

419 **Competing interests:** All authors have no conflict of interest to disclose. **Data and materials**  
420 **availability:** All the data presented in this study will be available upon request.

421

422 **Reference**

- 423
- 424 1. Chen HS, Chen YL, Harn HJ, Lin JS, Lin SZ. Stem cell therapy for tendon injury. *Cell*
  - 425 *Transplant*. 2012.
  - 426 2. Fleming BC, Spindler KP, Palmer MP, Magarian EM, Murray MM. Collagen-platelet
  - 427 composites improve the biomechanical properties of healing anterior cruciate ligament grafts in
  - 428 a porcine model. *Am J Sports Med*. 2009;37:1554-63.
  - 429 3. Spindler KP, Murray MM, Devin C, Nanney LB, Davidson JM. The central ACL defect as a
  - 430 model for failure of intra-articular healing. *J Orthop Res*. 2006;24:401-6.
  - 431 4. Tozer S, Duprez D. Tendon and ligament: development, repair and disease. *Birth Defects*
  - 432 *Res C Embryo Today*. 2005;75:226-36.
  - 433 5. Voleti PB, Buckley MR, Soslowky LJ. Tendon healing: repair and regeneration. *Annu Rev*
  - 434 *Biomed Eng*. 2012;14:47-71.
  - 435 6. Chen J, Xu J, Wang A, Zheng M. Scaffolds for tendon and ligament repair: review of the
  - 436 efficacy of commercial products. *Expert Rev Med Devices*. 2009;6:61-73.
  - 437 7. Milgrom C, Schaffler M, Gilbert S, van Holsbeeck M. Rotator-cuff changes in asymptomatic
  - 438 adults. The effect of age, hand dominance and gender. *J Bone Joint Surg Br*. 1995;77:296-8.
  - 439 8. Tempelhof S, Rupp S, Seil R. Age-related prevalence of rotator cuff tears in asymptomatic
  - 440 shoulders. *J Shoulder Elbow Surg*. 1999;8:296-9.
  - 441 9. Kew SJ, Gwynne JH, Enea D, Abu-Rub M, Pandit A, Zeugolis D, et al. Regeneration and
  - 442 repair of tendon and ligament tissue using collagen fibre biomaterials. *Acta Biomater*.
  - 443 2011;7:3237-47.
  - 444 10. Thomopoulos S, Williams GR, Gimbel JA, Favata M, Soslowky LJ. Variation of
  - 445 biomechanical, structural, and compositional properties along the tendon to bone insertion site.
  - 446 *J Orthop Res*. 2003;21:413-9.
  - 447 11. Juncosa-Melvin N, Boivin GP, Galloway MT, Gooch C, West JR, Butler DL. Effects of cell-
  - 448 to-collagen ratio in stem cell-seeded constructs for Achilles tendon repair. *Tissue Eng*.
  - 449 2006;12:681-9.
  - 450 12. Juncosa-Melvin N, Boivin GP, Galloway MT, Gooch C, West JR, Sklenka AM, et al. Effects
  - 451 of cell-to-collagen ratio in mesenchymal stem cell-seeded implants on tendon repair
  - 452 biomechanics and histology. *Tissue Eng*. 2005;11:448-57.
  - 453 13. Juncosa-Melvin N, Matlin KS, Holdcraft RW, Nirmalanandhan VS, Butler DL. Mechanical
  - 454 stimulation increases collagen type I and collagen type III gene expression of stem cell-collagen
  - 455 sponge constructs for patellar tendon repair. *Tissue Eng*. 2007;13:1219-26.
  - 456 14. Juncosa-Melvin N, Shearn JT, Boivin GP, Gooch C, Galloway MT, West JR, et al. Effects of
  - 457 mechanical stimulation on the biomechanics and histology of stem cell-collagen sponge
  - 458 constructs for rabbit patellar tendon repair. *Tissue Eng*. 2006;12:2291-300.
  - 459 15. Nirmalanandhan VS, Shearn JT, Juncosa-Melvin N, Rao M, Gooch C, Jain A, et al.
  - 460 Improving linear stiffness of the cell-seeded collagen sponge constructs by varying the
  - 461 components of the mechanical stimulus. *Tissue Eng Part A*. 2008;14:1883-91.
  - 462 16. Nourissat G, Diop A, Maurel N, Salvat C, Dumont S, Pigenet A, et al. Mesenchymal stem
  - 463 cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative
  - 464 rat model. *PLoS One*. 2010;5:e12248.
  - 465 17. Ouyang HW, Cao T, Zou XH, Heng BC, Wang LL, Song XH, et al. Mesenchymal stem cell
  - 466 sheets revitalize nonviable dense grafts: implications for repair of large-bone and tendon
  - 467 defects. *Transplantation*. 2006;82:170-4.
  - 468 18. Fan H, Liu H, Toh SL, Goh JC. Anterior cruciate ligament regeneration using mesenchymal
  - 469 stem cells and silk scaffold in large animal model. *Biomaterials*. 2009;30:4967-77.
  - 470 19. Fan H, Liu H, Wong EJ, Toh SL, Goh JC. In vivo study of anterior cruciate ligament
  - 471 regeneration using mesenchymal stem cells and silk scaffold. *Biomaterials*. 2008;29:3324-37.
  - 472 20. Hsu SL, Liang R, Woo SL. Functional tissue engineering of ligament healing. *Sports Med*
  - 473 *Arthrosc Rehabil Ther Technol*. 2010;2:12.

- 474 21. Devana SK, Kelley BV, McBride OJ, Kabir N, Jensen AR, Park SJ, et al. Adipose-derived  
475 Human Perivascular Stem Cells May Improve Achilles Tendon Healing in Rats. *Clinical*  
476 *orthopaedics and related research*. 2018;476:2091-100.
- 477 22. Goncalves AI, Gershovich PM, Rodrigues MT, Reis RL, Gomes ME. Human adipose tissue-  
478 derived tenomodulin positive subpopulation of stem cells: A promising source of tendon  
479 progenitor cells. *Journal of tissue engineering and regenerative medicine*. 2018;12:762-74.
- 480 23. Shen H, Jayaram R, Yoneda S, Linderman SW, Sakiyama-Elbert SE, Xia Y, et al. The effect  
481 of adipose-derived stem cell sheets and CTGF on early flexor tendon healing in a canine model.  
482 *Scientific reports*. 2018;8:11078.
- 483 24. Butler DL, Gooch C, Kinneberg KR, Boivin GP, Galloway MT, Nirmalanandhan VS, et al.  
484 The use of mesenchymal stem cells in collagen-based scaffolds for tissue-engineered repair of  
485 tendons. *Nat Protoc*. 2010;5:849-63.
- 486 25. Lee CH, Lee FY, Tarafder S, Kao K, Jun Y, Yang G, et al. Harnessing endogenous  
487 stem/progenitor cells for tendon regeneration. *The Journal of clinical investigation*.  
488 2015;125:2690-701.
- 489 26. Tarafder S, Minhas S, Yu RJ, Alex A, jeong J, Lee CH. A Combination of Oxo-M and 4-  
490 PPBP as a potential regenerative therapeutics for tendon injury. *Theranostics*. 2019;9:4241-54.
- 491 27. Li W, Li K, Wei W, Ding S. Chemical approaches to stem cell biology and therapeutics. *Cell*  
492 *stem cell*. 2013;13:270-83.
- 493 28. Hast MW, Zuskov A, Soslowsky LJ. The role of animal models in tendon research. *Bone*  
494 *Joint Res*. 2014;3:193-202.
- 495 29. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within  
496 degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. *Pharmaceutical research*.  
497 2000;17:100-6.
- 498 30. Thackaberry EA, Farman C, Zhong F, Lorget F, Staflin K, Cercillieux A, et al. Evaluation of  
499 the Toxicity of Intravitreally Injected PLGA Microspheres and Rods in Monkeys and Rabbits:  
500 Effects of Depot Size on Inflammatory Response. *Invest Ophthalmol Vis Sci*. 2017;58:4274-85.
- 501 31. Kumar VA, Taylor NL, Shi S, Wang BK, Jalan AA, Kang MK, et al. Highly angiogenic peptide  
502 nanofibers. *ACS Nano*. 2015;9:860-8.
- 503 32. Kumar VA, Taylor NL, Shi S, Wickremasinghe NC, D'Souza RN, Hartgerink JD. Self-  
504 assembling multidomain peptides tailor biological responses through biphasic release.  
505 *Biomaterials*. 2015;52:71-8.
- 506 33. Loppini M, Longo UG, Niccoli G, Khan WS, Maffulli N, Denaro V. Histopathological scores  
507 for tissue-engineered, repaired and degenerated tendon: a systematic review of the literature.  
508 *Current stem cell research & therapy*. 2015;10:43-55.
- 509 34. Lee CH, Shin HJ, Cho IH, Kang YM, Kim IA, Park KD, et al. Nanofiber alignment and  
510 direction of mechanical strain affect the ECM production of human ACL fibroblast. *Biomaterials*.  
511 2005;26:1261-70.
- 512 35. Akhtar R, Schwarzer N, Sherratt M, Watson R, Graham H, Trafford A, et al. Nanoindentation  
513 of histological specimens: mapping the elastic properties of soft tissues. 2009;24:638-46.
- 514 36. Sunwoo JY, Eliasberg CD, Carballo CB, Rodeo SA. The role of the macrophage in  
515 tendinopathy and tendon healing. *J Orthop Res*. 2020;38:1666-75.
- 516 37. Witherel CE, Graney PL, Spiller KL. In Vitro Model of Macrophage-Biomaterial Interactions.  
517 *Methods in molecular biology (Clifton, NJ)*. 2018;1758:161-76.
- 518 38. Howell KL, Kaji DA, Li TM, Montero A, Yeoh K, Nasser P, et al. Macrophage depletion  
519 impairs neonatal tendon regeneration. *FASEB journal : official publication of the Federation of*  
520 *American Societies for Experimental Biology*. 2021;35:e21618.
- 521 39. Marsolais D, Côté CH, Frenette J. Neutrophils and macrophages accumulate sequentially  
522 following Achilles tendon injury. *J Orthop Res*. 2001;19:1203-9.
- 523 40. Xu H-T, Lee C-W, Li M-Y, Wang Y-F, Yung PS-H, Lee OK-S. The shift in macrophages  
524 polarisation after tendon injury: A systematic review. *Journal of Orthopaedic Translation*.  
525 2020;21:24-34.

- 526 41. Nakagawa Y, Fortier LA, Mao JJ, Lee CH, Goodale MB, Koff MF, et al. Long-term  
527 Evaluation of Meniscal Tissue Formation in 3-dimensional-Printed Scaffolds With Sequential  
528 Release of Connective Tissue Growth Factor and TGF-beta3 in an Ovine Model. *Am J Sports*  
529 *Med.* 2019;47:2596-607.
- 530 42. Tarafder S, Koch A, Jun Y, Chou C, Awadallah MR, Lee CH. Micro-precise spatiotemporal  
531 delivery system embedded in 3D printing for complex tissue regeneration. *Biofabrication.*  
532 2016;8:025003.
- 533 43. Han HS, Niemeyer E, Huang Y, Kamoun WS, Martin JD, Bhaumik J, et al. Quantum  
534 dot/antibody conjugates for in vivo cytometric imaging in mice. *Proceedings of the National*  
535 *Academy of Sciences of the United States of America.* 2015;112:1350-5.
- 536 44. Kim SH, Park JH, Kwon JS, Cho JG, Park KG, Park CH, et al. NIR fluorescence for  
537 monitoring in vivo scaffold degradation along with stem cell tracking in bone tissue engineering.  
538 *Biomaterials.* 2020;258:120267.
- 539 45. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging,  
540 labelling and sensing. *Nature materials.* 2005;4:435-46.  
541  
542

543 **Figure legends**

544

545 **Figure 1.** Multi-domain peptide (MDP) hydrogel as controlled delivery vehicle for Oxo-M and 4-  
546 PPBP. MDP self-assembles supra-molecularly into nanofibers that encapsulate drugs, while  
547 maintaining shear thinning and shear recovery properties (**A**). This allows for facile aspiration  
548 and delivery as depots into tissue sites for localized release of small molecule drugs from  
549 biodegradable peptide scaffolds. Oxo-M and 4-PPBP loaded in fibrin gel were fully released by  
550 3 – 4 days (**B**), whereas they showed sustained release from MDP hydrogel up to 25 days (**C**).  
551 Tenogenic gene expressions were significantly higher in TSCs cultured under Transwell® inserts  
552 with fibrin and MDP hydrogel releasing Oxo-M and 4-PPBP (**C**). Oxo-M and 4-PPBP release  
553 from MDP hydrogel resulted in significantly higher gene expressions as compared to what  
554 released from fibrin (**C**) (n = 5 per group; \*: p<0.001 compared to fibrin group; #:p<0.001  
555 compared to control).

556

557 **Figure 2.** *In vitro* degradation of MDP and fibrin gel with and without Oxo-M and 4-PPBP.  
558 Fluorescence-labeled fibrin and MDP with or without Oxo-M and 4-PPBP (OP) were imaged (**A**)  
559 and the integral of signal intensities were quantified (**B**) (n = 3 per group).

560

561 **Figure 3.** *In vivo* tendon healing by 2 wks. The control ended up with scar-like healing with  
562 disrupt matrix and high cellularity (**A, D**), whereas fibrin and MDP delivered with Oxo-M and 4-  
563 PPBP showed notable improvement in tendon healing (**B, C, E, F**). Masson's trichrome showed  
564 higher collagen deposition in the healing zone with Oxo-M and 4-PPBP delivery via fibrin and  
565 MDP (**G-I**). Polarized PR images showed higher collagen orientation with MDP + OP as  
566 compared to fibrin + OP (**J-K**). There were some variances in the healing outcome with fibrin +  
567 OP (**B, E, H, K**) in comparison with more consistent outcome with MDP + OP (**C, F, I, L**).  
568 Quantitatively, MDP + OP resulted in significantly higher histological scores with a relatively  
569 small variance as compared to Fib + OP (**M**) (n = 10 – 25 per sample; \*:p<0.001 compared to  
570 control; #: p<0.001 compared to Fib + OP). Quantitative angular deviation (AD) value was  
571 significantly lower with MDP + OP as compared to fibrin + OP and control (**N**) (p<0.0001; n = 10  
572 – 15 per group). All images are representative best outcome for each group.

573

574 **Figure 4.** Modulus mapping by nanoindentation of tendon sections (**A-C**), showing more  
575 homogenous distribution of indentation moduli with MDP + OP as compared to Fib + OP. In  
576 violin plot of fold change in average  $E_{Eff}$  at healing zone in respect to corresponding intact area  
577 (**D**), Fib + OP and MDP + OP showed significant higher average  $E_{Eff}$  than control, with larger  
578 variance in Fib + OP than MDP + OP (n = 100 – 150 per group; \*:p<0.0001 compared to  
579 control).

580

581 **Figure 5.** Effect of Oxo-M and 4-PPBP on macrophage polarization (**A**) (\*:p<0.001 compared  
582 control). Immunofluorescence of macrophage and anti-inflammatory markers (**B**). The number  
583 of iNOS+ M1-like macrophages were lower with OP delivery (**B**). MDP + OP showed an  
584 increased number of CD163+ M2-like cells as compared to fibrin + OP (**B**). TIMP-3 and IL-10  
585 showed robust expression in MDP + OP group in comparison with Fib + OP (**B**).